Literature DB >> 22205299

Synaptic protein alterations in Parkinson's disease.

Ilse S Pienaar1, David Burn, Christopher Morris, David Dexter.   

Abstract

Alterations occur within distal neuronal compartments, including axons and synapses, during the course of neurodegenerative diseases such as Parkinson's disease (PD). These changes could hold important implications for the functioning of neural networks, especially since research studies have shown a loss of dendritic spines locating to medium spiny projection neurons and impaired axonal transport in PD-affected brains. However, despite ever-increasing awareness of the vulnerability of synapses and axons, inadequate understanding of the independent mechanisms regulating non-somatic neurodegeneration prevails. This has resulted in limited therapeutic strategies capable of targeting these distinct cellular compartments. Deregulated protein synthesis, folding and degrading proteins, and protein quality-control systems have repeatedly been linked with morphological and functional alterations of synapses in the PD-affected brains. Here, we review current understanding concerning the proteins involved in structural and functional changes that affect synaptic contact-points in PD. The collection of studies discussed emphasizes the need for developing therapeutics aimed at deregulated protein synthesis and degradation pathways operating at axonal and dendritic synapses for preserving "normal" circuitry and function, for as long as possible.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22205299     DOI: 10.1007/s12035-011-8226-9

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  193 in total

1.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

2.  Elongation factor-1alpha stabilizes microtubules in a calcium/calmodulin-dependent manner.

Authors:  R C Moore; N A Durso; R J Cyr
Journal:  Cell Motil Cytoskeleton       Date:  1998

3.  Quantitative synaptic alterations in the human neocortex during normal aging.

Authors:  E Masliah; M Mallory; L Hansen; R DeTeresa; R D Terry
Journal:  Neurology       Date:  1993-01       Impact factor: 9.910

4.  Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase.

Authors:  Alfredo Ramirez; André Heimbach; Jan Gründemann; Barbara Stiller; Dan Hampshire; L Pablo Cid; Ingrid Goebel; Ammar F Mubaidin; Abdul-Latif Wriekat; Jochen Roeper; Amir Al-Din; Axel M Hillmer; Meliha Karsak; Birgit Liss; C Geoffrey Woods; Maria I Behrens; Christian Kubisch
Journal:  Nat Genet       Date:  2006-09-10       Impact factor: 38.330

5.  Inhibition of α-synuclein aggregation by small heat shock proteins.

Authors:  Ilona B Bruinsma; Kim A Bruggink; Karsten Kinast; Alexandra A M Versleijen; Ine M J Segers-Nolten; Vinod Subramaniam; H Bea Kuiperij; Wilbert Boelens; Robert M W de Waal; Marcel M Verbeek
Journal:  Proteins       Date:  2011-08-26

6.  LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool.

Authors:  Giovanni Piccoli; Steven B Condliffe; Matthias Bauer; Florian Giesert; Karsten Boldt; Silvia De Astis; Andrea Meixner; Hakan Sarioglu; Daniela M Vogt-Weisenhorn; Wolfgang Wurst; Christian Johannes Gloeckner; Michela Matteoli; Carlo Sala; Marius Ueffing
Journal:  J Neurosci       Date:  2011-02-09       Impact factor: 6.167

7.  Caenorhabditis elegans rab-3 mutant synapses exhibit impaired function and are partially depleted of vesicles.

Authors:  M L Nonet; J E Staunton; M P Kilgard; T Fergestad; E Hartwieg; H R Horvitz; E M Jorgensen; B J Meyer
Journal:  J Neurosci       Date:  1997-11-01       Impact factor: 6.167

8.  Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.

Authors:  Juha-Matti Savola; Michael Hill; Mia Engstrom; Hannele Merivuori; Siegfried Wurster; Steven G McGuire; Susan H Fox; Alan R Crossman; Jonathan M Brotchie
Journal:  Mov Disord       Date:  2003-08       Impact factor: 10.338

Review 9.  The genetics of Parkinson's syndromes: a critical review.

Authors:  John Hardy; Patrick Lewis; Tamas Revesz; Andrew Lees; Coro Paisan-Ruiz
Journal:  Curr Opin Genet Dev       Date:  2009-05-04       Impact factor: 5.578

10.  Parkinson's disease mutations in PINK1 result in decreased Complex I activity and deficient synaptic function.

Authors:  Vanessa A Morais; Patrik Verstreken; Anne Roethig; Joél Smet; An Snellinx; Mieke Vanbrabant; Dominik Haddad; Christian Frezza; Wim Mandemakers; Daniela Vogt-Weisenhorn; Rudy Van Coster; Wolfgang Wurst; Luca Scorrano; Bart De Strooper
Journal:  EMBO Mol Med       Date:  2009-05       Impact factor: 12.137

View more
  13 in total

Review 1.  Cognitive decline in Parkinson disease.

Authors:  Dag Aarsland; Byron Creese; Marios Politis; K Ray Chaudhuri; Dominic H Ffytche; Daniel Weintraub; Clive Ballard
Journal:  Nat Rev Neurol       Date:  2017-03-03       Impact factor: 42.937

2.  Inflammation alters AMPA-stimulated calcium responses in dorsal striatal D2 but not D1 spiny projection neurons.

Authors:  Carissa D Winland; Nora Welsh; Alberto Sepulveda-Rodriguez; Stefano Vicini; Kathleen A Maguire-Zeiss
Journal:  Eur J Neurosci       Date:  2017-10-10       Impact factor: 3.386

Review 3.  Defective autophagy in Parkinson's disease: role of oxidative stress.

Authors:  Elzbieta Janda; Ciro Isidoro; Cristina Carresi; Vincenzo Mollace
Journal:  Mol Neurobiol       Date:  2012-08-17       Impact factor: 5.590

Review 4.  Dopaminergic Axons: Key Recitalists in Parkinson's Disease.

Authors:  Abhishek Kumar Mishra; Anubhuti Dixit
Journal:  Neurochem Res       Date:  2021-10-12       Impact factor: 3.996

5.  The Alzheimer disease BIN1 locus as a modifier of GBA-associated Parkinson disease.

Authors:  Z Gan-Or; I Amshalom; A Bar-Shira; M Gana-Weisz; A Mirelman; K Marder; S Bressman; N Giladi; A Orr-Urtreger
Journal:  J Neurol       Date:  2015-08-02       Impact factor: 4.849

6.  Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach.

Authors:  Erika Bereczki; Rui M Branca; Paul T Francis; Joana B Pereira; Jean-Ha Baek; Tibor Hortobágyi; Bengt Winblad; Clive Ballard; Janne Lehtiö; Dag Aarsland
Journal:  Brain       Date:  2018-02-01       Impact factor: 13.501

7.  Dynamin1 concentration in the prefrontal cortex is associated with cognitive impairment in Lewy body dementia.

Authors:  Julie Vallortigara; Sindhoo Rangarajan; David Whitfield; Amani Alghamdi; David Howlett; Tibor Hortobágyi; Mary Johnson; Johannes Attems; Clive Ballard; Alan Thomas; John O'Brien; Dag Aarsland; Paul Francis
Journal:  F1000Res       Date:  2014-05-13

8.  Evidence for Immune Response, Axonal Dysfunction and Reduced Endocytosis in the Substantia Nigra in Early Stage Parkinson's Disease.

Authors:  Anke A Dijkstra; Angela Ingrassia; Renee X de Menezes; Ronald E van Kesteren; Annemieke J M Rozemuller; Peter Heutink; Wilma D J van de Berg
Journal:  PLoS One       Date:  2015-06-18       Impact factor: 3.240

9.  Mitochondrial abnormality associates with type-specific neuronal loss and cell morphology changes in the pedunculopontine nucleus in Parkinson disease.

Authors:  Ilse S Pienaar; Joanna L Elson; Claudia Racca; Glyn Nelson; Douglass M Turnbull; Christopher M Morris
Journal:  Am J Pathol       Date:  2013-10-04       Impact factor: 4.307

10.  Anti-amyloid compounds inhibit α-synuclein aggregation induced by protein misfolding cyclic amplification (PMCA).

Authors:  Maria Eugenia Herva; Shahin Zibaee; Graham Fraser; Roger A Barker; Michel Goedert; Maria Grazia Spillantini
Journal:  J Biol Chem       Date:  2014-02-28       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.